Hypoxia Inducible Factor-1α Inactivation Unveils a Link between Tumor Cell Metabolism and Hypoxia-Induced Cell Death

Department of Oncology and Surgical Sciences, Oncology Section, University of Padova, Padova, Italy.
American Journal Of Pathology (Impact Factor: 4.59). 10/2008; 173(4):1186-201. DOI: 10.2353/ajpath.2008.071183
Source: PubMed


Hypoxia and the acquisition of a glycolytic phenotype are intrinsic features of the tumor microenvironment. The hypoxia inducible factor-1alpha (HIF-1alpha) pathway is activated under hypoxic conditions and orchestrates a complex transcriptional program that enhances cell survival. Although the consequences of HIF-1alpha inactivation in cancer cells have been widely investigated, only a few studies have addressed the role of HIF-1alpha in the survival of cancer cells endowed with different glycolytic capacities. In this study, we investigated this aspect in ovarian cancer cells. Hypoxia-induced toxicity was increased in highly glycolytic cells compared with poorly glycolytic cells; it was also associated with a sharp decrease in intracellular ATP levels and was prevented by glucose supplementation. Stable HIF-1alpha silencing enhanced hypoxia-induced cell death in vitro due to a lack of cell cycle arrest. Tumors bearing attenuated HIF-1alpha levels had similar growth rates and vascularization as did controls, but tumors showed higher proliferation levels and increased necrosis. Moreover, tumors formed by HIF-1alpha deficient cells had higher levels of lactate and lower ATP concentrations than controls as shown by metabolic imaging. The findings that such metabolic properties can affect the survival of cancer cells under hypoxic conditions and that these properties contribute to the determination of the consequences of HIF-1alpha inactivation could have important implications on the understanding of the effects of anti-angiogenic and HIF-1alpha-targeting drugs in cancer.

Download full-text


Available from: Elena Favaro
  • Source
    • "TGF-β1 and HIF-1α serve valuable functions in tumor angiogenesis and vascular remodeling, invasion and metastasis. Hypoxia and nutritional deficiency are the predominant features of solid tumors (15,16). Neovascularization in the tumor tissue is primarily mediated by vascular endothelial growth factor (VEGF) and its signaling pathway. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to determine how Endostar inhibits tumor angiogenesis and increases radiation sensitivity when combined with radiotherapy. In vitro studies were conducted to analyze the expression levels of transforming growth factor-β1 (TGF-β1), hypoxia-inducible factor 1 (HIF-1α) and basic fibroblast growth factor (bFGF) in lung adenocarcinoma A549 cells, using the antiangiogenesis drug Endostar combined with radiotherapy. In addition, lung adenocarcinoma A549 cell apoptosis was detected via Hoechst staining. The combination of Endostar with radiotherapy was investigated and the results indicated that this combination significantly inhibited tumor cell proliferation and TGF-β1, HIF-1α and bFGF expression. Changes in gene expression were found to promote apoptosis, thus, enhancing the inhibition of tumor angiogenesis and ultimately inhibiting tumor cell growth, invasion and metastasis.
    Full-text · Article · Apr 2014 · Experimental and therapeutic medicine
  • Source
    • "The role of HIF1α has been well documented in cancers originating in the ovary. Tumor xenografts obtained from stable HIF1α-silenced ovarian cancer cells show increased cell death and necrosis [61], and the expression levels of HIF1α have been proposed as an independent prognostic factor in patients with epithelial ovarian tumors [62]. HIF1α activity is regulated by several pathways, including the mitogen-activated protein kinase cascade, and p38α has been demonstrated to be involved in the stabilization of HIF1α in various normal and cancer cell types [63, 64]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is sensitive to chemotherapy with platinum compounds; however, the therapy success rate is significantly lowered by a high incidence of recurrence and by the acquisition of drug resistance. These negative outcomes mainly depend on altered apoptotic and drug resistance pathways, determining the need for the design of new therapeutic strategies to improve patient survival. This challenge has become even more critical because it has been recognized that hindering uncontrolled cell growth is not sufficient as the only curative approach. In fact, while current therapies are mostly conceived to impair survival of highly proliferating cells, several lines of research are now focusing on cancer-specific features to specifically target malignant cells with the aim of avoiding drug resistance and reducing adverse effects. Recently, great interest has been generated by the identification of metabolic reprogramming mechanisms occurring in cancer cells, such as the increase in glycolysis levels. In this light, pharmacologic manipulation of relevant pathways involved in cancer-specific metabolism and drug resistance could prove an effective approach to treat ovarian cancer patients.
    Full-text · Article · Mar 2012 · Journal of Oncology
  • Source
    • "Conversely, acute apoptosis was almost absent. Interestingly, a recent study demonstrated a dramatic increase of hypoxia-induced cell death in HIF-1∝-depleted ovarian cancer cells [46]. Similar to PP2A inhibition, HIF-1∝ depletion prevented cancer cells from arresting in the G1/S phase during hypoxic conditions. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The hypoxic microenvironment of glioblastoma multiforme (GBM) is thought to increase resistance to cancer therapies. Recent evidence suggests that hypoxia induces protein phosphatase 2A (PP2A), a regulator of cell cycle and cell death. The effects of PP2A on GBM tumor cell proliferation and survival during hypoxic conditions have not been studied. Expression of PP2A subunits and HIF-α proteins was measured in 65 high-grade astrocytoma and 18 non-neoplastic surgical brain specimens by western blotting. PP2A activity was measured by an immunoprecipitation assay. For in vitro experiments, GBM-derived tumor stem cell-like cells (TSCs) were exposed to severe hypoxia produced by either CoCl₂ or 1% O₂. PP2A activity was inhibited either by okadaic acid or by shRNA depletion of the PP2A C subunit. Effects of PP2A activity on cell cycle progression and cell survival during hypoxic conditions were assessed using flow cytometry. In our patient cohort, PP2A activity was positively correlated with HIF-1∝ protein expression (P = 0.002). Patients with PP2A activity levels above 160 pMP had significantly worse survival compared to patients with levels below this threshold (P = 0.002). PP2A activity was an independent predictor of survival on multivariable analysis (P = 0.009). In our in vitro experiments, we confirmed that severe hypoxia induces PP2A activity in TSCs 6 hours after onset of exposure. PP2A activity mediated G1/S phase growth inhibition and reduced cellular ATP consumption in hypoxic TSCs. Conversely, inhibition of PP2A activity led to increased cell proliferation, exhaustion of intracellular ATP, and accelerated P53-independent cell death of hypoxic TSCs. Our results suggest that PP2A activity predicts poor survival in GBM. PP2A appears to reduce the metabolic demand of hypoxic TSCs and enhances tumor cell survival. Modulation of PP2A may be a potential target for cancer therapy.
    Full-text · Article · Jan 2012 · PLoS ONE
Show more